Antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): In vitro and in vivo

AAPS PharmSciTech

Volumn 11, Issue 2, 2010, Pages 752-759

  Huang, Yue ^a   Chen, Xiao Mei ^a   Zhao, Bing Xiang ^a   Ke, Xi Yu ^a   Zhao, Bo Jun ^a   Zhao, Xin ^a   Wang, Ying ^a   Zhang, Xuan ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Antiangiogenic activity; Migration; Paclitaxel; Proliferation; Sterically stabilized liposomes

Indexed keywords

CREMOPHOR; LIPOSOME; PACLITAXEL; STERICALLY STABILIZED LIPOSOME CONTAINING PACLITAXEL; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; DELAYED RELEASE FORMULATION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIALYSIS; ENDOTHELIUM CELL; FEMALE; FILM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; DRUG FORMULATION; DRUG STABILITY; NUDE MOUSE; PATHOLOGY; PROCEDURES; SYNTHESIS; TREATMENT OUTCOME; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG COMPOUNDING; DRUG STABILITY; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; PACLITAXEL; TREATMENT OUTCOME;

EID: 77955668144     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9430-z     Document Type: Article

References (40)

1. Frei 3rd E, Elias A, Wheeler C, Richardson P, Hryniuk W. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin Cancer Res. 1998;4:2027-37.
2. Nieto Y. The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. Haematologica. 2003;88:201-11.
3. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-36.
4. Laquente B, Viñals F, Germà JR. Metronomic chemotherapy: an antiangiogenic scheduling. Clin Transl Oncol. 2007;9:93-8.
5. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878-86.
6. Kamat AA, Kim TJ, Landen Jr CN, Lu C, Han LY, Lin YG et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007;67:281-8.
7. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843-9.
8. Ng SS, Figg WD, Sparreboom A. Taxane-mediated antiangiogenesis in vitro:influence of formulation vehicles and binding proteins. Cancer Res. 2004;64:821-4.
9. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615-26.
10. Straubinger RM, Arnold RD, Zhou R, Mazurchuk R, Slack JE. Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res. 2004;24:397-404.
11. Sharma A, Sharma US, Straubinger RM. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. Cancer Lett. 1996;107:265-72.
12. Huwyler J, Drewe J, Krähenbuhl S. Tumor targeting using liposomal antineoplastic drugs. Int J Nanomedicine. 2008;3:21-9.
13. Moghimi SM, Patel HM. Opsonophagocytosis of liposomes by peritoneal macrophages and bone marrow reticuloendothelial cells. Biochim Biophys Acta. 1992;1135:269-74.
14. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature. 1996;11(380):561-2.
15. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55:3752-6.
16. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm. 2007;338:317-26.
17. Yang T, Choi MK, Cui FD, Lee SJ, Chung SJ, Shim CK et al. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm Res. 2007;24:2402-11.
18. Crosasso P, Ceruti M, Brusa P, Arpicco S, Dosio F, Cattel L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release. 2000;63:19-30.
19. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albuminbound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99-105.
20. Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremophor-EL free formulation of paclitaxel. Nanomedicine (Lond). 2007;2:415-23.
21. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317-24.
22. Ng SS, Sparreboom A, Shaked Y, Lee C, Man S, Desai N et al. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus Cremophor EL-based paclitaxel. Clin Cancer Res. 2006;12:4331-8.
23. Ashton AW, Yokota R, John G, Zhao S, Suadicani SO, Spray DC et al. Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A (2). J Biol Chem. 1999;274:35562-70.
24. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1:1112-6.
25. Bijman MN, Van Nieuw Amerongen GP, Laurens N, van Hinsbergh VW, Boven E. Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther. 2006;5:2348-57.
26. Liu XR, Wu KC, Huang Y, Sun JB, Ke XY, Wang JC et al. In vitro and in vivo studies on plasma-to-blood ratio of paclitaxel in human, rabbit and rat blood fractions. Biol Pharm Bull. 2008;31:1215-20.
27. Aapro MS, Von Minckwitzb G. Molecular basis for the development of novel taxanes in the treatment of metastatic breast cancer. EJC Supplements. 2008;6:3-11.
28. Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K et al. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol. 2003;120:476-82.
29. Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res. 2003;9:2335-41.
30. Strieth S, Eichhorn ME, Sauer B, Schulze B, Teifel M, Michaelis U et al. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer. 2004;110:117-24.
31. Strieth S, Nussbaum CF, Eichhorn ME, Fuhrmann M, Teifel M, Michaelis U et al. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer. 2008;122:452-60.
32. Strieth S, Eichhorn ME, Werner A, Sauer B, Teifel M, Michaelis U et al. Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin. Clin Cancer Res. 2008;14:4603-11.
33. Bode C, Trojan L, Weiss C, Kraenzlin B, Michaelis U, Teifel M et al. Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer. Oncol Rep. 2009;22:321-6.
34. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999;59:1454-7.
35. Ellis AG, Webster LK. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. Cancer Chemother Pharmacol. 1999;43:13-8.
36. Marcel Musteata F, Pawliszyn J. Determination of free concentration of paclitaxel in liposome formulation. J Pharm Pharm Sci. 2006;9:231-7.
37. Fielding RM. Liposomal drug delivery. Advantages and limitations from a clinical pharmacokinetic and therapeutic perspective. Clin Pharmacokinet. 1991;21:155-64.
38. Campbell RB, Ying B, Kuesters GM, Hemphill R. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci. 2009;98:411-29.
39. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26:57-64.
40. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994;54:3352-6.